• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Knowles Lori Lynn returned $22,317 worth of shares to the company (10,237 units at $2.18), closing all direct ownership in the company (SEC Form 4)

    9/24/24 2:42:56 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Knowles Lori Lynn

    (Last) (First) (Middle)
    100 DOMAIN DRIVE

    (Street)
    EXETER NH 03833

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    VAPOTHERM INC [ VAPO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/20/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/20/2024 D 7,862 D $2.18(1) 0 D
    Common Stock 09/20/2024 D 2,375 D $2.18(2) 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $18.48 09/20/2024 D 1,089 (3) 07/27/2032 Common Stock 1,089 $0 0 D
    Explanation of Responses:
    1. Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.
    2. The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.
    3. This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.
    /s/ James A. Lightman, as Attorney In Fact 09/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VAPO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vapotherm Announces Closing of Merger

    EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

    9/20/24 10:33:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Reports Second Quarter 2024 Financial Results

    EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

    8/12/24 5:15:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

    EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

    6/17/24 6:55:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

    4/A - VAPOTHERM INC (0001253176) (Issuer)

    10/4/23 4:11:34 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 5:01:08 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 4:43:19 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 4:14:26 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    SEC Filings

    View All

    SEC Form 15-12G filed by Vapotherm Inc.

    15-12G - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 11:32:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Vapotherm Inc.

    EFFECT - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 12:15:03 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Vapotherm Inc.

    EFFECT - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 12:15:04 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vapotherm downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

    5/6/22 7:28:09 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

    4/7/22 7:25:32 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Piper Sandler reiterated coverage on Vapotherm with a new price target

    Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

    2/25/21 7:36:13 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Leadership Updates

    Live Leadership Updates

    View All

    Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

    TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

    9/8/23 8:30:00 AM ET
    $IART
    $VAPO
    Medical/Dental Instruments
    Health Care

    Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    12/7/22 4:05:00 PM ET
    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

    SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

    9/24/24 7:04:57 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

    SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

    9/20/24 10:32:59 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Vapotherm Inc.

    SC 13G - VAPOTHERM INC (0001253176) (Subject)

    7/18/24 7:24:17 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Financials

    Live finance-specific insights

    View All

    Vapotherm To Report Second Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

    7/25/23 4:30:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Reports First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

    5/3/23 4:10:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm To Report First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

    4/27/23 4:30:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care